NOEMI REYES: Open Payments
NPI 1568174415 · LUBBOCK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$720 in 36 payments from 16 companies in 2025. Trend: 2023 $159 · 2024 $465 · 2025 $720
Food & beverage: $720
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $200 |
| GlaxoSmithKline, LLC. | 5 | $97 |
| Sumitomo Pharma America, Inc. | 3 | $66 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| PFIZER INC. | 2 | $41 |
| Lilly USA, LLC | 2 | $36 |
| Exact Sciences Corporation | 2 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
| Merck Sharp & Dohme LLC | 1 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
Products named: VRAYLAR, TRELEGY ELLIPTA, GEMTESA, CAPLYTA, VERQUVO, Sunosi, VOQUEZNA, Quviviq.
Industry payments across TX — which companies pay providers there.
